would be for NYMX to go to J&J and offer to screen 10,000 high risk patients for $99.00 (or less if possible) per patient as part of the Reminyl launch. J&J would probably kick in part of the price to help Dr.'s identify patients at risk. Tying the diagnostic to a therapy, especially one in launch mode, could significantly raise the visability of the test to physicians. To accelerate the usage and acceptance of this test, you need major pharma sponsor support.
and a (been there,done that)might be the case.The recent news releases mention wide acceptance by Intern l pharmas.It just may be that companies doing clinical research requiring AD confirmed subjects,went to nymox for the diagnostic a long while back.No one has a therapy !!!Reminyl doesn t slow the progression of AD in any way. So mox might want its test tied to own therapuetic compounds being developed from its own patented drug target.They consider themselves a leader in this field,and are much closer to actually stopping the disease than those looking to treat symptoms.
Forge is right and it is obvious. Also obvious was 4 times average trading volume yesterday based on refried beans that you call news. Hmmm. Another obvious, and IMHO predictable event, was the plunge today. "Life is a bitch and then you die?" You could be right about that.But, hey, it waz just a cliche... right?